RP-A501 — Topline data
H2 2026
The Company also remains on track to provide a comprehensive Danon disease program update in the second half of 2026.Source filing
RCKT biotech catalysts & pipeline
ROCKET PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
RP-A501 — Regulatory decision
H2 2026
Rocket is actively engaging with the FDA to seek alignment on the path to dosing additional patients and completing the pivotal Phase 2 trial and expects to provide an update on the regulatory pathway in the second half of 2026.Source filing
RP-A601 — Regulatory decision
H2 2026
Rocket continues to engage with the FDA regarding alignment on the design of a potential pivotal study of RP-A601 in PKP2-ACM with regulatory update expected in the second half of 2026.Source filing
RP-A701 — Initial data
H2 2026
Patient screening and enrollment has begun, with initial patient dosing anticipated in the second half of 2026.Source filing